Avidity Biosciences, Inc. (RNA)

24,30 +0,14 (+0,58%) Ab 09:41AM EDT. Markt geöffnet.

Avidity Biosciences, Inc.

10578 Science Center Drive
Suite 125
San Diego, CA 92121
United States
858 401 7900
https://www.aviditybiosciences.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 253

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Troy Edward Wilson J.D., Ph.D.	Co-Founder & Chairman	67,5k	N/A	1969
Ms. Sarah Boyce	President, CEO & Director	1,05M	1,08M	1972
Mr. Michael F. MacLean	Chief Financial & Chief Business Officer	701,64k	N/A	1966
Dr. W. Michael Flanagan Ph.D.	Chief Scientific & Technical Officer	678,74k	N/A	1962
Ms. Teresa McCarthy	Chief Human Resources Officer	665,14k	N/A	1964
Mr. Eric B. Mosbrooker	Chief Strategy Officer	42,5k	N/A	1968
Prof. Mark E. Davis	Scientific Founder, Member of Scientific Advisory Board and Member of Board of Managers	N/A	N/A	N/A
Dr. Frank P. McCormick Ph.D.	Scientific Founder & Member of Scientific Advisory Board	N/A	N/A	1950
Mr. Geoffrey M. Grande C.F.A.	VP of Investor Relation & Corporate Communication	N/A	N/A	N/A
Dr. John W. Wallen III	VP of Intellectual Property, General Counsel & Secretary	N/A	N/A	1958

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Corporate Governance

Avidity Biosciences, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 9. Die grundlegenden Scores sind Audit: 8, Vorstand: 9, Shareholderrechte: 8, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.